指南与共识乳腺癌放疗

美国放射肿瘤学会全乳放疗循证指南执行摘要

Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.
指南 / 共识 · Pract Radiat Oncol · 2018-03-12

美国放射肿瘤学会(ASTRO)组织工作组,基于系统文献综述和预设共识方法,针对全乳放疗(WBI)的分割方案、瘤床补量指征与剂量分割及治疗计划技术提出推荐。对接受WBI的浸润性乳腺癌女性,首选大分割方案为4000 cGy分15次或4250 cGy分16次;补量应基于共享决策,并推荐将接受超过105%处方剂量的乳腺组织体积最小化、瘤床勾画目标为至少95%处方剂量覆盖。

要点

  • 浸润性乳腺癌全乳放疗首选大分割:4000 cGy/15次或4250 cGy/16次。
  • 瘤床补量需基于共享决策,考虑患者、肿瘤和治疗因素。
  • 计划时最小化接受>105%处方剂量的乳腺组织体积。

核心结论

  • 全乳放疗首选大分割方案为4000 cGy分15次或4250 cGy分16次。
  • 补量使用应基于考虑患者、肿瘤和治疗因素的共享决策。
  • 计划时应最小化接受超过105%处方剂量的乳腺组织体积,瘤床勾画目标为至少95%处方剂量覆盖。

研究设计与样本

  • ASTRO召集工作组,基于系统文献综述和预设共识构建方法制定指南。
  • 工作组针对5个关键问题:WBI剂量分割、瘤床补量指征与剂量分割、WBI和瘤床补量的治疗计划技术。

主要发现

  • 对接受WBI(伴或不伴低位腋窝照射)的浸润性乳腺癌女性,首选大分割WBI 4000 cGy/15次或4250 cGy/16次。
  • 指南讨论了可能或应该影响分割决策的因素。
  • 工作组明确了推荐或建议使用或省略补量的特定亚组及剂量推荐。

关键数值与推荐

  • 首选大分割WBI剂量为4000 cGy分15次或4250 cGy分16次。
  • 计划时接受>105%处方剂量的乳腺组织体积应最小化。
  • 瘤床勾画目标为至少95%处方剂量覆盖。
  • 心脏、对侧乳腺、肺及其他正常组织剂量应最小化。

临床怎么用

  • 对浸润性乳腺癌全乳放疗优先选择大分割方案4000 cGy/15次或4250 cGy/16次。
  • 补量决策采用共享决策,参考指南推荐的特定亚组及剂量。
  • 治疗计划中限制乳腺高剂量体积(>105%处方剂量),确保瘤床至少95%处方剂量覆盖,并最小化正常组织剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The purpose of this guideline is to offer recommendations on fractionation for whole breast irradiation (WBI) with or without a tumor bed boost and guidance on treatment planning and delivery. METHODS AND MATERIALS: The American Society for Radiation Oncology (ASTRO) convened a task force to address 5 key questions focused on dose-fractionation for WBI, indications and dose-fractionation for tumor bed boost, and treatment planning techniques for WBI and tumor bed boost. Guideline recommendations were based on a systematic literature review and created using a predefined consensus-building methodology supported by ASTRO-approved tools for grading evidence quality and recommendation strength. RESULTS: For women with invasive breast cancer receiving WBI with or without inclusion of the low axilla, the preferred dose-fractionation scheme is hypofractionated WBI to a dose of 4000 cGy in 15 fractions or 4250 cGy in 16 fractions. The guideline discusses factors that might or should affect fractionation decisions. Use of boost should be based on shared decision-making that considers patient, tumor, and treatment factors, and the task force delineates specific subgroups in which it recommends or suggests use or omission of boost, along with dose recommendations. When planning, the volume of breast tissue receiving >105% of the prescription dose should be minimized and the tumor bed contoured with a goal of coverage with at least 95% of the prescription dose. Dose to the heart, contralateral breast, lung, and other normal tissues should be minimized. CONCLUSIONS: WBI represents a significant portion of radiation oncology practice, and these recommendations are intended to offer the groundwork for defining evidence-based practice for this common and important modality. This guideline also seeks to promote appropriately individualized, shared decision-making regarding WBI between physicians and patients.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018. PMID: 29545124. doi:10.1016/j.prro.2018.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。